Short answer
Electromed, Inc. (ELMD) filed its fiscal 2026 10-K annual report with the SEC on Aug 25, 2026. It reported revenue of $74M (+15.3% year over year) and net income of $11M.
FY2026 key financial metrics · XBRL
- Revenue
- $74M
- +15.3% YoY
- Net income
- $11M
- +49.9% YoY
- Operating margin
- 18.8%
- +3.7 pp YoY
- Gross margin
- 78.5%
- +0.5 pp YoY
- EPS (diluted)
- $1.30
- +52.9% YoY
- ROE
- 20.9%
- +3.5 pp YoY
- Operating cash flow
- $10M
- −15.2% YoY
Source: XBRL data from the Electromed, Inc. (ELMD) FY2026 10-K on SEC EDGAR. USD.
Electromed, Inc. FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Direct-to-patient and provider sales of SmartVest HFCWO airway clearance therapy systems, bypassing traditional HME channels
- New product introduction: SmartVest Clearway launched Nov 2022, featuring touchscreen interface, single-hose patented design, lighter <14 lb generator for enhanced patient experience
- Strategic emphasis shift: Increased focus on bronchiectasis market, growing 12% annually with underpenetrated ~16% therapy adoption in ~1 million diagnosed US patients
- Quantitative highlights: Fiscal 2026 revenue $73.4M US-based (95.3% homecare), 58 direct sales employees, R&D spend up to $1.31M (1.8% revenue), 197 employees total
- Noteworthy 2026 fact: Publication and presentation of recent 2023-2025 clinical studies validating HFCWO efficacy in bronchiectasis and COPD, underscoring under-prescription and growth opportunity
Management Discussion & Analysis
- Revenue $73.8M, up 15.3% YoY driven by homecare growth: $66.6M (+16.3%), hospital $3.4M (+9.6%), distributor $3.3M (+12.7%)
- Gross margin 78.5% vs 78.1%; Operating income $13.9M (+43.7%) margin approx. 18.8% vs 15.1% in prior year
- Best segment: Homecare revenue $66.6M (+$9.3M); Worst: Other revenue $0.4M (-34.7%)
- Operating cash flow $9.7M; Capex $1.25M; Share repurchase $3.9M; Dividends not mentioned
- Fiscal 2027 risks: Supply chain constraints, inflationary component costs, geopolitical conflict; strategy to expand sales force and bronchiectasis market presence
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.